Call the Office of Patient Recruitment at 800-411-1222 to speak with one of our Information Specialists.
For those who are deaf, hard-of-hearing, or speech impaired, the Federal Relay Service provides free telecommunications relay services (TRS).
Se habla español.
Trial of MVA-BN-Brachyury Vaccine in Patients with Advanced Cancer
Researchers at the National Institutes of Health are testing the safety of MVA-BN-Brachyury vaccine for adults who have advanced metastatic cancer. The vaccine is designed to target cells responsible for tumor growth. Researchers hope the vaccine will help the immune system kill tumor cells and slow down cancer growth. If you have recurring advanced metastatic cancer that is not surgically removable and standard therapies have not been effective, you may be eligible to participate.
You can participate if you:
- Are 18 years of age or older
- Have an advanced metastatic cancer that has spread to other parts of the body
- Have had failed standard therapies
- Have no evidence of being immunocompromised
- Are not pregnant or breastfeeding
Study design includes:
- Complete physical exam and medical history
- Blood and urine tests
- Imaging, such as CT scans or MRIs
- Electrocardiogram (EKG or ECG)
- Vaccine during weeks 1, 4, and 7 with at least 2 nights of hospitalization after each vaccine
- Follow-up visits 1 month and 3 months after last dose of vaccine
- Financial assistance with travel and lodging provided
The NIH Clinical Center is America's Research Hospital and is located in Bethesda, Maryland, on the Metro Red line (Medical Center stop).
For more information:
NIH Clinical Center
Office of Patient Recruitment
800-411-1222 (refer to study # 20-C-0001)
800-877-8339 TTY / ASCII
Se habla español
Or go online:
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
NOTE: PDF documents require the free Adobe Reader.
This page last updated on 03/10/2020